Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

“With 3 years of follow-up now, the majority of patients achieved a response [with blinatumomab plus ponatinib].”

Hannah Goulart, MD, a hematology oncology fellow at The University of Texas MD Anderson Cancer Center, discussed long-term follow-up findings from a phase 2 trial (NCT03263572) investigating first-line blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.